 Jeffrey Kaplan
Concepts (378)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biofilms | 39 | 2025 | 272 | 9.160 |
Why?
| | Aggregatibacter actinomycetemcomitans | 22 | 2024 | 27 | 3.980 |
Why?
| | Staphylococcus epidermidis | 15 | 2025 | 77 | 3.270 |
Why?
| | Glycoside Hydrolases | 14 | 2025 | 39 | 3.110 |
Why?
| | Bacterial Proteins | 24 | 2025 | 910 | 2.900 |
Why?
| | Anti-Bacterial Agents | 17 | 2025 | 1856 | 2.270 |
Why?
| | Polysaccharides, Bacterial | 13 | 2015 | 70 | 2.140 |
Why?
| | Bacterial Adhesion | 18 | 2018 | 103 | 2.050 |
Why?
| | Staphylococcus aureus | 9 | 2018 | 436 | 1.810 |
Why?
| | Actinobacillus pleuropneumoniae | 5 | 2013 | 5 | 1.420 |
Why?
| | DNA, Bacterial | 11 | 2024 | 333 | 1.420 |
Why?
| | Kingella kingae | 3 | 2016 | 12 | 1.230 |
Why?
| | Microbial Sensitivity Tests | 10 | 2025 | 366 | 1.010 |
Why?
| | Acetylglucosamine | 6 | 2008 | 13 | 0.950 |
Why?
| | Benzoyl Peroxide | 1 | 2025 | 2 | 0.920 |
Why?
| | Propionibacteriaceae | 1 | 2025 | 2 | 0.920 |
Why?
| | Propionibacterium acnes | 1 | 2025 | 10 | 0.920 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2024 | 238 | 0.860 |
Why?
| | Micrococcal Nuclease | 1 | 2024 | 26 | 0.850 |
Why?
| | Actinobacillus Infections | 7 | 2008 | 7 | 0.830 |
Why?
| | Prosthesis-Related Infections | 6 | 2011 | 98 | 0.820 |
Why?
| | Deoxyribonuclease I | 5 | 2018 | 40 | 0.790 |
Why?
| | Adhesins, Bacterial | 6 | 2010 | 40 | 0.770 |
Why?
| | Bacteria | 5 | 2014 | 874 | 0.720 |
Why?
| | Extracellular Space | 2 | 2012 | 129 | 0.700 |
Why?
| | Amoxicillin | 2 | 2024 | 35 | 0.680 |
Why?
| | Povidone-Iodine | 2 | 2018 | 11 | 0.660 |
Why?
| | Staphylococcal Skin Infections | 1 | 2018 | 35 | 0.570 |
Why?
| | Molecular Sequence Data | 17 | 2012 | 2917 | 0.540 |
Why?
| | Cetylpyridinium | 4 | 2009 | 7 | 0.510 |
Why?
| | Neisseriaceae Infections | 2 | 2016 | 6 | 0.510 |
Why?
| | beta-Lactams | 2 | 2016 | 34 | 0.490 |
Why?
| | Virulence Factors | 3 | 2024 | 162 | 0.460 |
Why?
| | Exotoxins | 4 | 2008 | 16 | 0.440 |
Why?
| | Pasteurellaceae | 3 | 2010 | 3 | 0.430 |
Why?
| | Genes, Bacterial | 5 | 2004 | 165 | 0.410 |
Why?
| | Genome, Bacterial | 2 | 2012 | 150 | 0.410 |
Why?
| | Bacterial Capsules | 1 | 2013 | 31 | 0.400 |
Why?
| | Arthritis, Infectious | 1 | 2012 | 73 | 0.350 |
Why?
| | Sodium Dodecyl Sulfate | 2 | 2009 | 26 | 0.340 |
Why?
| | Drug Resistance, Bacterial | 4 | 2018 | 189 | 0.340 |
Why?
| | Pasteurellaceae Infections | 2 | 2024 | 2 | 0.340 |
Why?
| | Fimbriae, Bacterial | 3 | 2016 | 34 | 0.330 |
Why?
| | Recombination, Genetic | 1 | 2011 | 206 | 0.330 |
Why?
| | Pancreatic Neoplasms | 4 | 2024 | 889 | 0.330 |
Why?
| | Extracellular Matrix | 2 | 2014 | 556 | 0.330 |
Why?
| | Periodontitis | 5 | 2006 | 53 | 0.320 |
Why?
| | Staphylococcus | 2 | 2007 | 75 | 0.320 |
Why?
| | Enzyme Therapy | 1 | 2009 | 4 | 0.310 |
Why?
| | beta-Glucans | 1 | 2008 | 21 | 0.300 |
Why?
| | Mouth | 2 | 2015 | 88 | 0.300 |
Why?
| | Down-Regulation | 1 | 2011 | 638 | 0.290 |
Why?
| | Aggressive Periodontitis | 3 | 2003 | 4 | 0.290 |
Why?
| | Polysaccharides | 2 | 2008 | 87 | 0.290 |
Why?
| | Haemophilus influenzae | 1 | 2009 | 63 | 0.290 |
Why?
| | Disinfectants | 1 | 2009 | 46 | 0.290 |
Why?
| | Mouth Mucosa | 2 | 2007 | 90 | 0.290 |
Why?
| | Fusobacterium nucleatum | 1 | 2008 | 4 | 0.290 |
Why?
| | Dental Plaque | 1 | 2008 | 18 | 0.280 |
Why?
| | Bacterial Infections | 1 | 2010 | 245 | 0.270 |
Why?
| | Adenocarcinoma | 3 | 2024 | 895 | 0.270 |
Why?
| | Cefamandole | 1 | 2007 | 1 | 0.270 |
Why?
| | Galactans | 1 | 2007 | 5 | 0.260 |
Why?
| | Polyurethanes | 1 | 2007 | 38 | 0.260 |
Why?
| | Bacterial Physiological Phenomena | 3 | 2014 | 60 | 0.260 |
Why?
| | Sequence Analysis, DNA | 6 | 2009 | 817 | 0.260 |
Why?
| | Humans | 45 | 2025 | 140898 | 0.250 |
Why?
| | Surface-Active Agents | 1 | 2007 | 92 | 0.250 |
Why?
| | Drug Resistance | 1 | 2007 | 149 | 0.250 |
Why?
| | Recombinant Proteins | 5 | 2018 | 1361 | 0.230 |
Why?
| | Swine Diseases | 1 | 2005 | 8 | 0.230 |
Why?
| | O Antigens | 2 | 2003 | 9 | 0.230 |
Why?
| | Acne Vulgaris | 1 | 2025 | 26 | 0.230 |
Why?
| | Fimbriae Proteins | 3 | 2016 | 21 | 0.220 |
Why?
| | Drug Synergism | 1 | 2025 | 369 | 0.210 |
Why?
| | Serotyping | 4 | 2008 | 33 | 0.210 |
Why?
| | Species Specificity | 4 | 2011 | 577 | 0.210 |
Why?
| | Acetylglucosaminidase | 1 | 2003 | 7 | 0.210 |
Why?
| | Animals | 17 | 2024 | 37579 | 0.200 |
Why?
| | Genetic Variation | 3 | 2002 | 994 | 0.200 |
Why?
| | Neisseria | 1 | 2002 | 2 | 0.200 |
Why?
| | Bacteria, Anaerobic | 1 | 2002 | 25 | 0.190 |
Why?
| | Base Sequence | 6 | 2012 | 2169 | 0.180 |
Why?
| | Gene Transfer, Horizontal | 2 | 2016 | 35 | 0.180 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2021 | 68 | 0.180 |
Why?
| | Gram-Negative Bacteria | 1 | 2001 | 79 | 0.170 |
Why?
| | Amino Acid Sequence | 7 | 2008 | 2152 | 0.170 |
Why?
| | Barrett Esophagus | 1 | 2023 | 160 | 0.170 |
Why?
| | Polymerase Chain Reaction | 5 | 2008 | 1052 | 0.170 |
Why?
| | Osteopontin | 1 | 2020 | 31 | 0.170 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2021 | 170 | 0.170 |
Why?
| | Gastroesophageal Reflux | 1 | 2023 | 244 | 0.160 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 38 | 0.160 |
Why?
| | Macrophages | 1 | 2008 | 1559 | 0.160 |
Why?
| | Microfluidics | 2 | 2010 | 58 | 0.160 |
Why?
| | Codon | 2 | 1998 | 92 | 0.160 |
Why?
| | DNA Transposable Elements | 4 | 2008 | 120 | 0.160 |
Why?
| | Polystyrenes | 3 | 2004 | 38 | 0.150 |
Why?
| | Esophageal Neoplasms | 1 | 2023 | 336 | 0.150 |
Why?
| | Microfluidic Analytical Techniques | 2 | 2010 | 81 | 0.150 |
Why?
| | Sus scrofa | 1 | 2018 | 60 | 0.150 |
Why?
| | Colony Count, Microbial | 2 | 2009 | 123 | 0.140 |
Why?
| | Escherichia coli | 5 | 2010 | 835 | 0.140 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.140 |
Why?
| | Weight Gain | 1 | 2021 | 537 | 0.140 |
Why?
| | Liver | 2 | 2020 | 1815 | 0.130 |
Why?
| | Pancreatic Cyst | 1 | 2018 | 48 | 0.130 |
Why?
| | Epithelial Cells | 3 | 2010 | 1113 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2020 | 263 | 0.130 |
Why?
| | Adipose Tissue | 1 | 2021 | 645 | 0.130 |
Why?
| | Endopeptidase K | 1 | 2016 | 18 | 0.130 |
Why?
| | Biopsy | 2 | 2018 | 1069 | 0.130 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 110 | 0.120 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 353 | 0.120 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2015 | 8 | 0.120 |
Why?
| | Mutagenesis, Insertional | 3 | 2008 | 65 | 0.120 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 391 | 0.110 |
Why?
| | Myositis | 1 | 2015 | 52 | 0.110 |
Why?
| | Nausea | 1 | 2015 | 111 | 0.110 |
Why?
| | Acinetobacter baumannii | 1 | 2014 | 22 | 0.110 |
Why?
| | Muscle, Smooth | 1 | 2015 | 154 | 0.110 |
Why?
| | Air | 1 | 2014 | 43 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2001 | 1156 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2016 | 143 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 60 | 0.110 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2007 | 614 | 0.110 |
Why?
| | Bone Resorption | 1 | 2015 | 84 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 85 | 0.110 |
Why?
| | Abdominal Pain | 1 | 2015 | 144 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2014 | 167 | 0.110 |
Why?
| | Anilides | 1 | 2014 | 81 | 0.110 |
Why?
| | Environmental Microbiology | 1 | 2014 | 57 | 0.110 |
Why?
| | Plankton | 1 | 2014 | 7 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 72 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 2056 | 0.100 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 206 | 0.100 |
Why?
| | Surface Properties | 4 | 2012 | 414 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2019 | 740 | 0.100 |
Why?
| | Molecular Weight | 1 | 2013 | 327 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2014 | 3487 | 0.090 |
Why?
| | Female | 15 | 2024 | 75540 | 0.090 |
Why?
| | Pancreas | 1 | 2014 | 326 | 0.090 |
Why?
| | Coated Materials, Biocompatible | 1 | 2012 | 65 | 0.090 |
Why?
| | Cell Survival | 3 | 2012 | 1129 | 0.090 |
Why?
| | Tobramycin | 1 | 2011 | 52 | 0.090 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4407 | 0.090 |
Why?
| | Microscopy, Electron | 2 | 2003 | 440 | 0.090 |
Why?
| | Cell Communication | 1 | 2013 | 316 | 0.090 |
Why?
| | Genetic Complementation Test | 2 | 2008 | 66 | 0.090 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2014 | 285 | 0.090 |
Why?
| | Biomarkers, Tumor | 2 | 2014 | 1243 | 0.090 |
Why?
| | Culture Media | 3 | 2010 | 163 | 0.080 |
Why?
| | Orthopedic Equipment | 1 | 2010 | 5 | 0.080 |
Why?
| | Pyridines | 1 | 2014 | 553 | 0.080 |
Why?
| | Treatment Failure | 1 | 2011 | 353 | 0.080 |
Why?
| | Focal Nodular Hyperplasia | 1 | 2010 | 7 | 0.080 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2002 | 545 | 0.080 |
Why?
| | Bacterial Toxins | 2 | 2002 | 104 | 0.080 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2007 | 62 | 0.080 |
Why?
| | Escherichia coli Proteins | 1 | 2011 | 202 | 0.080 |
Why?
| | Fungi | 1 | 2011 | 152 | 0.080 |
Why?
| | DNA Primers | 2 | 2007 | 508 | 0.080 |
Why?
| | Titanium | 1 | 2010 | 85 | 0.080 |
Why?
| | Disease Transmission, Infectious | 1 | 2010 | 69 | 0.080 |
Why?
| | Osteoblasts | 1 | 2010 | 136 | 0.080 |
Why?
| | Drug Interactions | 2 | 2008 | 403 | 0.080 |
Why?
| | Sodium Hypochlorite | 1 | 2009 | 5 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 143 | 0.080 |
Why?
| | Convection | 1 | 2008 | 6 | 0.080 |
Why?
| | Mutation | 5 | 2009 | 3999 | 0.080 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 321 | 0.070 |
Why?
| | Enzymes | 1 | 2009 | 65 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2008 | 391 | 0.070 |
Why?
| | Chlorhexidine | 1 | 2009 | 24 | 0.070 |
Why?
| | Flagella | 1 | 1989 | 27 | 0.070 |
Why?
| | Azo Compounds | 1 | 2008 | 29 | 0.070 |
Why?
| | Phosphoenolpyruvate Sugar Phosphotransferase System | 1 | 2008 | 4 | 0.070 |
Why?
| | Diffusion | 1 | 2008 | 121 | 0.070 |
Why?
| | Catalytic Domain | 2 | 2008 | 223 | 0.070 |
Why?
| | Obesity | 1 | 2021 | 3000 | 0.070 |
Why?
| | Pancreatectomy | 2 | 2024 | 262 | 0.070 |
Why?
| | Caenorhabditis elegans | 1 | 2011 | 332 | 0.070 |
Why?
| | Male | 12 | 2024 | 69893 | 0.070 |
Why?
| | beta-N-Acetylhexosaminidases | 1 | 2007 | 11 | 0.070 |
Why?
| | Congo Red | 1 | 2007 | 10 | 0.070 |
Why?
| | Phylogeny | 2 | 2002 | 1005 | 0.070 |
Why?
| | Gene Order | 1 | 2007 | 27 | 0.070 |
Why?
| | Tritium | 1 | 2007 | 72 | 0.070 |
Why?
| | Detergents | 1 | 2007 | 45 | 0.070 |
Why?
| | Quorum Sensing | 1 | 2008 | 74 | 0.070 |
Why?
| | Micelles | 1 | 2007 | 39 | 0.070 |
Why?
| | Chromosomes, Bacterial | 1 | 2007 | 9 | 0.070 |
Why?
| | Ampicillin | 1 | 2007 | 14 | 0.070 |
Why?
| | Glycosyltransferases | 1 | 2007 | 16 | 0.070 |
Why?
| | Periodic Acid | 1 | 2007 | 2 | 0.070 |
Why?
| | Pancreatin | 1 | 2007 | 6 | 0.070 |
Why?
| | Ligands | 2 | 2008 | 667 | 0.060 |
Why?
| | Glycogen Storage Disease Type IV | 1 | 2006 | 4 | 0.060 |
Why?
| | 1,4-alpha-Glucan Branching Enzyme | 1 | 2006 | 4 | 0.060 |
Why?
| | Carbohydrate Sequence | 2 | 2008 | 28 | 0.060 |
Why?
| | Middle Aged | 8 | 2024 | 34487 | 0.060 |
Why?
| | Colorectal Neoplasms | 1 | 2014 | 805 | 0.060 |
Why?
| | Peptide Hydrolases | 1 | 2007 | 113 | 0.060 |
Why?
| | Cohort Studies | 3 | 2024 | 5789 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2604 | 0.060 |
Why?
| | Pleuropneumonia | 1 | 2005 | 1 | 0.060 |
Why?
| | Carbohydrate Conformation | 1 | 2005 | 14 | 0.060 |
Why?
| | Gene Deletion | 1 | 2007 | 388 | 0.060 |
Why?
| | Hydrogels | 2 | 2012 | 687 | 0.060 |
Why?
| | Virulence | 2 | 2003 | 267 | 0.060 |
Why?
| | Static Electricity | 1 | 2005 | 113 | 0.060 |
Why?
| | Prenatal Diagnosis | 1 | 2006 | 190 | 0.060 |
Why?
| | Mice | 5 | 2021 | 18057 | 0.050 |
Why?
| | Carbohydrate Metabolism | 1 | 2004 | 61 | 0.050 |
Why?
| | Aged | 6 | 2024 | 24666 | 0.050 |
Why?
| | Primates | 1 | 2005 | 133 | 0.050 |
Why?
| | Protein Structure, Secondary | 1 | 2005 | 368 | 0.050 |
Why?
| | Lactoferrin | 1 | 2003 | 40 | 0.050 |
Why?
| | Child, Preschool | 2 | 2016 | 11462 | 0.050 |
Why?
| | Catheterization | 1 | 2004 | 182 | 0.050 |
Why?
| | Polyethylene Glycols | 1 | 2008 | 639 | 0.050 |
Why?
| | Adult | 7 | 2020 | 39134 | 0.050 |
Why?
| | Metaplasia | 1 | 2023 | 58 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 2156 | 0.050 |
Why?
| | Transcription, Genetic | 3 | 2020 | 1485 | 0.050 |
Why?
| | Sequence Analysis, Protein | 1 | 2002 | 31 | 0.050 |
Why?
| | Agar | 1 | 2002 | 11 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2010 | 768 | 0.050 |
Why?
| | Protein Structure, Tertiary | 1 | 2005 | 858 | 0.050 |
Why?
| | Bacteriological Techniques | 1 | 2003 | 66 | 0.050 |
Why?
| | Child | 3 | 2016 | 22313 | 0.050 |
Why?
| | Swine | 1 | 2005 | 809 | 0.050 |
Why?
| | Promoter Regions, Genetic | 2 | 2009 | 1241 | 0.050 |
Why?
| | Conserved Sequence | 1 | 2002 | 238 | 0.050 |
Why?
| | DNA, Ribosomal | 1 | 2002 | 94 | 0.050 |
Why?
| | Mice, Obese | 1 | 2021 | 66 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2003 | 377 | 0.040 |
Why?
| | Aromatase Inhibitors | 1 | 2021 | 58 | 0.040 |
Why?
| | Esophagoscopy | 1 | 2023 | 214 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1396 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 423 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 95 | 0.040 |
Why?
| | Genotype | 2 | 2003 | 1862 | 0.040 |
Why?
| | Phenotype | 2 | 2010 | 3172 | 0.040 |
Why?
| | Tamoxifen | 1 | 2021 | 203 | 0.040 |
Why?
| | Kinetics | 1 | 2004 | 1651 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2001 | 145 | 0.040 |
Why?
| | Protein Precursors | 1 | 2001 | 134 | 0.040 |
Why?
| | Mutagenesis | 1 | 2001 | 182 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1822 | 0.040 |
Why?
| | Coculture Techniques | 2 | 2010 | 244 | 0.040 |
Why?
| | Alleles | 1 | 2002 | 883 | 0.040 |
Why?
| | Temperature | 1 | 2002 | 669 | 0.040 |
Why?
| | Adolescent | 4 | 2010 | 22027 | 0.040 |
Why?
| | Protein Binding | 1 | 2005 | 2238 | 0.040 |
Why?
| | Genetic Code | 1 | 1998 | 22 | 0.040 |
Why?
| | Base Composition | 1 | 1998 | 79 | 0.040 |
Why?
| | ROC Curve | 1 | 2020 | 589 | 0.040 |
Why?
| | Cyst Fluid | 1 | 2018 | 21 | 0.030 |
Why?
| | Carcinoembryonic Antigen | 1 | 2018 | 37 | 0.030 |
Why?
| | Infant | 1 | 2012 | 9790 | 0.030 |
Why?
| | Hydrolysis | 2 | 2008 | 196 | 0.030 |
Why?
| | Cell Movement | 1 | 2002 | 982 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2018 | 50 | 0.030 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2018 | 57 | 0.030 |
Why?
| | Substrate Specificity | 2 | 2008 | 384 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2010 | 2813 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1067 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 985 | 0.030 |
Why?
| | Endosonography | 1 | 2018 | 153 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 7899 | 0.030 |
Why?
| | Matched-Pair Analysis | 1 | 2016 | 38 | 0.030 |
Why?
| | Giant Cells | 1 | 2016 | 22 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2024 | 11125 | 0.030 |
Why?
| | Cell Line | 2 | 2012 | 2879 | 0.030 |
Why?
| | Binding Sites | 2 | 2010 | 1315 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2016 | 217 | 0.030 |
Why?
| | CD3 Complex | 1 | 2015 | 106 | 0.030 |
Why?
| | Monosaccharides | 1 | 2014 | 13 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1968 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2016 | 380 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1786 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2014 | 80 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2014 | 207 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 2015 | 2522 | 0.030 |
Why?
| | Intestine, Small | 1 | 2015 | 157 | 0.030 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 97 | 0.030 |
Why?
| | Time Factors | 3 | 2010 | 6944 | 0.030 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2014 | 188 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 1007 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 1022 | 0.030 |
Why?
| | Lymphocytes | 1 | 2015 | 394 | 0.020 |
Why?
| | Microscopy | 1 | 2014 | 155 | 0.020 |
Why?
| | Radiography | 1 | 2015 | 844 | 0.020 |
Why?
| | Models, Molecular | 2 | 2008 | 1602 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2014 | 956 | 0.020 |
Why?
| | Colon | 1 | 2015 | 296 | 0.020 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 229 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 295 | 0.020 |
Why?
| | Mice, Nude | 1 | 2014 | 689 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2791 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3578 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2014 | 368 | 0.020 |
Why?
| | Polymethacrylic Acids | 1 | 2012 | 61 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2014 | 442 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1536 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1761 | 0.020 |
Why?
| | Rats | 2 | 2015 | 5594 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 903 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1962 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1491 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2014 | 1195 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5895 | 0.020 |
Why?
| | Propidium | 1 | 2010 | 8 | 0.020 |
Why?
| | 3T3 Cells | 1 | 2010 | 154 | 0.020 |
Why?
| | Cell Shape | 1 | 2010 | 57 | 0.020 |
Why?
| | Alloys | 1 | 2010 | 38 | 0.020 |
Why?
| | Siphoviridae | 1 | 2009 | 2 | 0.020 |
Why?
| | Artificial Gene Fusion | 1 | 2009 | 3 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2009 | 5 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 365 | 0.020 |
Why?
| | Protein Hydrolysates | 1 | 2008 | 6 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2010 | 468 | 0.020 |
Why?
| | Caseins | 1 | 2008 | 22 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 887 | 0.020 |
Why?
| | Nucleotides | 1 | 2009 | 127 | 0.020 |
Why?
| | Buffers | 1 | 2008 | 56 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2009 | 272 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 418 | 0.020 |
Why?
| | Oligosaccharides | 1 | 2008 | 60 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1430 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2008 | 203 | 0.020 |
Why?
| | Multigene Family | 1 | 1989 | 202 | 0.020 |
Why?
| | Rifampin | 1 | 2008 | 80 | 0.020 |
Why?
| | Microscopy, Atomic Force | 1 | 2008 | 128 | 0.020 |
Why?
| | Orthopedics | 1 | 2010 | 154 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2008 | 140 | 0.020 |
Why?
| | Cercopithecidae | 1 | 2007 | 8 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2009 | 401 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2008 | 363 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2008 | 219 | 0.020 |
Why?
| | Phosphates | 1 | 2008 | 179 | 0.020 |
Why?
| | Teichoic Acids | 1 | 2007 | 14 | 0.020 |
Why?
| | Abortion, Eugenic | 1 | 2006 | 3 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2007 | 377 | 0.020 |
Why?
| | Hemolysis | 1 | 2008 | 207 | 0.020 |
Why?
| | Knee Prosthesis | 1 | 2006 | 26 | 0.020 |
Why?
| | Equipment Design | 1 | 2008 | 525 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2010 | 566 | 0.020 |
Why?
| | Thermodynamics | 1 | 2008 | 424 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 2006 | 46 | 0.020 |
Why?
| | Genome Components | 1 | 2006 | 2 | 0.020 |
Why?
| | Tissue Engineering | 1 | 2010 | 429 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 556 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 4060 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 307 | 0.010 |
Why?
| | Protein Transport | 1 | 2007 | 448 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2012 | 1999 | 0.010 |
Why?
| | Membrane Transport Proteins | 1 | 2006 | 154 | 0.010 |
Why?
| | Calcium | 1 | 2010 | 1190 | 0.010 |
Why?
| | Spodoptera | 1 | 2003 | 40 | 0.010 |
Why?
| | Computer Simulation | 1 | 2008 | 1011 | 0.010 |
Why?
| | Alveolar Bone Loss | 1 | 2003 | 9 | 0.010 |
Why?
| | Genetic Testing | 1 | 2006 | 463 | 0.010 |
Why?
| | Maxilla | 1 | 2003 | 36 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2003 | 532 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2497 | 0.010 |
Why?
| | Adenosine Triphosphatases | 1 | 2003 | 159 | 0.010 |
Why?
| | Iron | 1 | 2003 | 323 | 0.010 |
Why?
| | Signal Transduction | 1 | 2014 | 5148 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1989 | 2822 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2003 | 624 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1438 | 0.010 |
Why?
| | United States | 1 | 2016 | 15195 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2016 | 16315 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 6257 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2006 | 2082 | 0.010 |
Why?
| | Pregnancy | 1 | 2006 | 7035 | 0.010 |
Why?
|
|
Kaplan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|